1. Huberman E, Callaham MF (1979) Induction of terminal differentiation
in human promyelocytic leukemia cells by tumor
promoting agents. Proc Natl Acad Sci USA 76:1293–1297
2. Lotem J, Sachs L (1979) Regulation of differentiation in mouse
and human myeloid leukemic cells by phorbol esters and the
mechanism of tumor promotion. Proc Natl Acad Sci USA
76:5158–5162
3. Rovera G, Santoli D, Damsky C (1979) Human promyelocytic
cells in culture differentiate into macrophage-like cells when
treated with a phorbol diester. Proc Natl Acad Sci USA
76:2779–2783
4. Koeffler HP (1980) Phorbol diester-induced macrophage differentiation
of leukemic blasts from patients with human
myelogenous leukemia. J Clin Invest 66:1101–1108
5. Koeffler HP, Bar-Eli M, Territo MC (1981) Phorbol ester effect
on differentiation of human myeloid leukemia cell lines blocked
at different stages of maturation. Cancer Res 41:919–926
6. Polliack A, Leizerowitz R, Korkesh A, Gurfel D, Gamliel H,
Galili U (1982) Exposure to TPA in vitro as an aid in the
classification of blasts in human myelogenous and lymphoid
leukemias. Am J Hematol 13:199–211
7. Shkolnick T, Schlossman SF, Griffin JD (1985) Acute undifferentiated
leukemia: induction of partial differentiation by
phorbol ester. Leuk Res 9:11–17
8. Abrahm JL, Gerson SL, Hoxie JA, Tannenbaum SH, Cassileth
PA, Cooper RA (1986) Differential effects of phorbol esters on
normal myeloid precursors and leukemic cells. Cancer Res
46:3711–3716
9. Hofmann J (1997) The potential for isoenzyme-selective
modulation of protein kinase C. FASEB J 11:649
10. Mochly-Rosen D, Kauvar LM (1998) Modulating protein
kinase C signal transduction. Adv Pharmacol 44:91
11. Newton AC (1995) Protein kinase C structure, function and
regulation. J Biol Chem 270:28495
794
12. Kazanietz MG (2000) Eyes wide shut: protein kinase C isoenzymes
are not the only receptors for the phorbol ester tumor
promoters. Mol Carcinog 28:5
13. Hunter T (2000) Signaling 2000 and beyond. Cell 100:113
14. Meinhardt G, Roth J, Hass R (2000) Activation of protein
kinase C relays distinct signaling pathways in the same cell
type: differentiation and caspase-mediated apoptosis. Cell
Death Differ 7:795–803
15. Garrington TP, Johnson GL (1999) Organization and regulation
of MAPK signaling pathways. Curr Opin Cell Biol 11:211
16. Vojtek AB, Der CJ (1998) Increasing complexity of the ras
signaling pathway. J Biol Chem 273:19925
17. Hill CS, Treisman R (1995) Transcriptional regulation by
extracellular signals: mechanisms and specificity. Cell 80:199
18. Treisman R (1996) Regulation of transcription by MAP kinase
casacades. Curr Opin Cell Biol 8:205
19. Schwartz MA, Baron V (2000) Interactions between mitogenic
stimuli, or, a thousand and one connections. Curr Opin Cell
Biol 11:197
20. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM,
Blalock WL, Franklin RA, McCunbrey JA (2003) Signal
transduction mediated by the Ras/Raf/MEK/ERK pathway
from cytokine receptors to transcription factors: potential targeting
for therapeutic intervention. Leukemia 17:1263–1293
21. Platanias LC (2003) Map kinase signaling pathways and hematologic
malignancies. Blood 101:4667–4679
22. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling:
transient versus sustained extracellular signal regulated
kinase activation. Cell 80:179
23. Keyse SM (2000) Protein phosphatases and the regulation of
MAPK signaling. Curr Opin Cell Biol 12:186
24. Bhalla US (2004) Models of cell signaling pathways. Curr Opin
Genet Dev 14:375–381
25. Mochly-Rosen D, Kauvar LM (2000) Pharmacologic regulation
of network kinetics by protein kinase C localization. Semin
Immunol 12:55
26. Mochly-Rosen D, Gordon AS (1998) Anchoring proteins for
protein kinase C: a means for isozyme specificity. FASEB J 12:35
27. Kelly L, Clark J, Gilliland DG (2002) Comprehensive genotypic
analysis of leukemia:clinical and therapeutic implications.
Curr Opin Oncol 14:10
28. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki
S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H,
Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R
(1999) Prognostic implications of Flt-3 and N-ras gene mutations
in acute myeloid leukemia. Blood 93:3074–3080
29. Beaupre DM, Kuzrock R (1999) RAS and leukemia. J Clin
Oncol 17:1071–1079
30. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M,
Saito H (1997) Constitutive activation of the mitogen-activated
protein kinase pathway in acute leukemia cells. Leukemia
11:479–484
31. Kim S-C, Hahn J-S, Min Y-H, Yoo N-C, Ko Y-W, Lee W-J
(1999) Constitutive activation of extracellular signal-regulated
kinase in human acute leukemias: combined role of activation
of MEK, hyperexpression of extracellular signal regulated kinase,
and down-regulation of a phosphatase, PAC1. Blood
93:3893
32. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T,
Saito H, Naoe T (2000) Tandem duplicated Flt-3 constitutively
activates STA5 and MAP kinase and introduces autonomous
cell growth in IL-3-dependent cell lines. Oncogene 19:624–631
33. Morgan MA, Dolp O, Reuter WM (2001) Cell cyle dependent
activation of mitogen-activated protein kinase kinase (MEK-1/
2) in myeloid leukemia cell lines and induction of growth
inhibition and apoptosis by inhibitors of RAS signaling. Blood
97:1823
34. Schaar DG, Liu H, Sharma S, Ting Y, Martin J, Krier C,
Ciardella M, Osman M, Goodell L, Notterman DA, Strair RK
(2005) 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced
dual-specificity phosphatase expression and AML cell survival.
Leuk Res 29:1171–1179
35. Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF, Liu XJ, Cao GS,
Newmark HL, Conney AH, Chang RL (1998) Effect of intravenous
12-O-tetradecanoylphorbol-13-acetate (TPA) in patients
with myelocytic leukemia:preliminary studies on therapeutic
efficacy and toxicity. Proc Natl Acad Sci USA 95:5357–5361
36. Strair RK, Schaar D, Goodell L, Aisner J, Chin K-V, Eid J,
Senzon R, Knox B, Cui XX, Han ZT, Newmark HL, Rabson
AB, Chang RL, Conney A (2002) Administration of a phorbol
ester to patients with hematologic malignancies: Preliminary
results from a phase I clinical trial of 12-O-tetradecanoylphorbol-
13-acetate. Clin Cancer Res 8:2512–2518
37. Cui XX, Chang RL, Zheng X, Woodward D, Strair R, Conney
A (2002) A sensitive bioassay for measuring blood levels of 12-
O-tetradecanoylphorbol-13-acetate (TPA) in patients: preliminary
pharmacokinetic studies. Oncol Res 13:169–174
38. 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced increase in
depressed white blood cell counts in patients treated with
cytotoxic cancer chemotherapeutic drugs. (1998) Proc Natl Acad Sci 95:5362–5365
39. A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate
for patients with relapsed/refractory malignancies. Cancer Chemother
Pharmacol (2006) 57: 789–795
40. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079827/
41. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997264/
